HonCode

Go Back   HER2 Support Group Forums > Breast Cancer Meeting Highlights
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Breast Cancer Meeting Highlights News fro recent ASCO and San Antonio Meetings

Reply
 
Thread Tools Display Modes
Old 05-18-2014, 02:12 PM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post Primary analysis of the prospective, randomized, single-blinded phase II trial of AE3

Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.



Abstract No:
638
Attend this session at the
2014 ASCO Annual Meeting!


Session: Breast Cancer - HER2/ER
Type: General Poster Session
Time: Monday June 2, 8:00 AM to 11:45 AM
Location: S Hall A2
Personalize your Meeting experience with a suggested or customized itinerary!

Author(s): Elizabeth Ann Mittendorf, Erika J Schneble, Sonia A. Perez, James T Symanowski, Ritesh Patil, Timothy J. Vreeland, John S. Berry, Alfred F Trappey, Guy T. Clifton, Eric von Hofe, Alexandros Ardavanis, Sathibalan Ponniah, Nathan M. Shumway, Michael Papamichail, George Earl Peoples; The University of Texas MD Anderson Cancer Center, Houston, TX; San Antonio Military Medical Center, San Antonio, TX; Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece; Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; Roswell Park Cancer Institute, Buffalo, NY; Antigen Express, Worcester, MA; Department of Clinical Oncology, Cancer Immunology Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece; Cancer Vaccine Development Program, United States Military Cancer Institute, USUHS, Bethesda, MD
Abstract Disclosures

Abstract:

Background: AE37 is the Ii-Key hybrid of the HER2 peptide AE36 (HER2 aa:776-790). It is a MHC class II epitope capable of stimulating CD4+ helper T-cells. We have completed accrual to a prospective, randomized, multi-center, phase II trial of the AE37 vaccine for prevention of breast cancer recurrence. Here the planned primary analysis of disease free survival (DFS) is presented. Methods: The trial randomized clinically disease-free, node positive or high-risk node negative patients (pts) with any level of HER2 expression to receive AE37 + GM-CSF (VG) or GM-CSF alone (CG) following standard of care therapy. Pts received 6 monthly intradermal inoculations during the primary vaccine series (PVS) followed by four boosters administered every 6 months. Statistical analysis was performed in the following groups: intention-to-treat (ITT) as the entire randomly assigned trial population, HER2 non-overexpressing (nOE) pts with IHC 1/2+ or FISH- tumors regardless of ER/PR status, and triple negative breast cancer (TNBC) pts with HER2 nOE and ER/PR-tumors. Results: With 298 pts (VG= 153, CG= 145) enrolled, there are no differences between groups with respect to age, rate of node positivity, tumor grade, tumor size, ER/PR status, and HER2 over-expression (all p > 0.05). The vaccine is safe and well tolerated with no grade 3 local toxicities and 1 pt experiencing grade 3 systemic toxicity. DFS analyses by Kaplan Meier demonstrated a 12% relative reduction in recurrence (RRR) in the ITT population (19/153 v 20/145 events; HR(CI) 0.89 (0.47, 1.66), p=0.70), a 40% RRR in HER2 nOE pts (10/76 v 14/78 events; HR(CI) 0.60 (0.26, 1.35), p=0.21), and 60% in TNBC pts (4/25 v 9/25; HR(CI) 0.40 (0.12, 1.32), p=0.12). Conclusions: AE37 + GM-CSF is a novel vaccine that is safe and well tolerated with minimal toxicity. The primary analysis of this prospective, randomized, single-blinded phase II trial demonstrates benefit in patients with HER2 nOE tumors, especially those with triple negative tumors. These data justify a phase III trial evaluating AE37 administered in the adjuvant setting to a HER nOE or specifically TNBC population. Clinical trial information: NCT00524277.
'lizbeth is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 12:20 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter